Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Celltrion, Inc.
  6. Summary
    A068270   KR7068270008

CELLTRION, INC.

(A068270)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Korea Stock Exchange
06/16/2021 06/17/2021 06/18/2021 06/21/2021 06/22/2021 Date
271500 269000 270000 280500 274000 Last
399618 387652 476193 1005972 534404 Volume
-1.27% -0.92% +0.37% +3.89% -2.32% Change
Estimated financial data (e)
Sales 2021 2 341 B 2,06 B 2,06 B
Net income 2021 762 B 0,67 B 0,67 B
Net cash position 2021 634 B 0,56 B 0,56 B
P/E ratio 2021 49,6x
Yield 2021 0,00%
Sales 2022 2 777 B 2,45 B 2,45 B
Net income 2022 861 B 0,76 B 0,76 B
Net cash position 2022 1 145 B 1,01 B 1,01 B
P/E ratio 2022 43,8x
Yield 2022 0,01%
Capitalization 37 427 B 32 903 M 32 973 M
EV / Sales 2021 15,7x
EV / Sales 2022 13,1x
Nbr of Employees 2 072
Free-Float 69,0%
More Financials
Company
Celltrion, Inc. is a Korea-based company mainly engaged in the production and sale of biopharmaceuticals. Along with subsidiaries, the Company operates its business through three segments. The Biopharmaceutical segment is involved in the manufacturing and sale of biopharmaceutical products such as multivitamins, blood circulation remedies, blood cancer treatments and breast cancer treatments. The Chemical... 
More about the company
Ratings of Celltrion, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about CELLTRION, INC.
06/15AstraZeneca antibody cocktail fails to prevent COVID-19 in large trial
RE
06/15MARKET CHATTER : Celltrion's COVID-19 Treatment Reduces Viral Load
MT
06/14Celltrion Rallies After Positive Data on Covid-19 Treatment
DJ
06/13CELLTRIONá : says trial shows antibody COVID-19 treatment to be safe and effecti..
RE
06/07MARKET CHATTER : Celltrion to Invest $47 Million in British Biotech Firm Iksuda ..
MT
05/21Celltrion's Breast Cancer Drug Captures 47% Share of Japan Market
MT
05/07EU regulator begins real-time review of GSK-Vir COVID-19 antibody drug
RE
05/03S.Korean stocks fall for 5th day on worries over partial lifting of short-sel..
RE
04/20COVID Quick Test by South Korea's Celltrion and Humasis Gets US FDA Approval ..
MT
04/01CELLTRIONá : Healthcare receives positive CHMP opinion for subcutaneous formulat..
AQ
03/25MARKET CHATTER : South Korea's Pharma Exports Surge 23% in 2020
MT
03/09MARKET CHATTER : Celltrion Initiates Clinical Trials for Heart Condition Treatme..
MT
03/03CELLTRIONá : EMA review of regdanvimab for COVID-19 to support national decision..
AQ
03/03S.Korean shares end higher as U.S. yields retreat, China policy anxiety eases
RE
02/26EU regulator advises use of Regeneron antibody cocktail for COVID-19
RE
More news
News in other languages on CELLTRION, INC.
06/15MÄRKTE ASIEN/Uneinheitlich - Sydney und Seoul auf Rekordjagd
06/15MÄRKTE ASIEN/Tokio und Sydney fest - Schanghai und Hongkong leichter
06/14MÄRKTE ASIEN/Tokio freundlich - Rekordhoch in Seoul
05/07VACCINIá : Ue; aperti a dialogo, Usa sblocchi export (Stampa)
05/04MÄRKTE ASIEN/Erholt - Steigende Corona-Zahlen belasten in Taiwan
More news
Analyst Recommendations on CELLTRION, INC.
More recommendations
Chart CELLTRION, INC.
Duration : Period :
Celltrion, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELLTRION, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 274 000,00 KRW
Average target price 341 397,06 KRW
Spread / Average Target 24,6%
EPS Revisions
Managers and Directors
NameTitle
Wu-Sung Ki Chief Executive Officer & Director
Ho-Seop Lee Finance Director
Jung-Jin Seo Chairman
Sung-Han Lee Head-Legal & Compliance Support
Dong-Il Kim Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.-24.79%32 903
MODERNA, INC.111.89%83 614
LONZA GROUP AG13.26%52 103
IQVIA HOLDINGS INC.35.88%46 660
SEAGEN INC.-9.40%28 728
HANGZHOU TIGERMED CONSULTING CO., LTD14.49%24 977